Silvan Tuerkcan
Stock Analyst at Citizens JMP
(4.72)
# 755
Out of 5,096 analysts
433
Total ratings
42.2%
Success rate
15.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterated: Buy | $50 → $65 | $70.13 | -7.31% | 54 | Oct 19, 2026 | |
| FHTX Foghorn Therapeutics | Downgraded: Hold | n/a | $2.13 | - | 5 | Oct 1, 2026 | |
| CLLS Cellectis | Downgraded: Hold | n/a | $1.04 | - | 24 | Sep 15, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $21 → $26 | $17.28 | +50.46% | 38 | Aug 10, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $8 → $11 | $4.00 | +175.00% | 44 | Jun 23, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | n/a | $1.45 | - | 7 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $28 → $30 | $11.66 | +157.29% | 45 | Apr 28, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $86 → $80 | $49.99 | +60.03% | 56 | Jan 30, 2026 | |
| NUVB Nuvation Bio | Reiterated: Buy | $8 → $10 | $4.59 | +117.86% | 6 | Nov 20, 2025 | |
| BNTC Benitec Biopharma | Reiterated: Buy | $20 → $22 | $8.49 | +159.13% | 26 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $31.64 | n/a | 4 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $6 | $0.508 | n/a | 12 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.61 | n/a | 12 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $6.00 | n/a | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.33 | n/a | 29 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $4.44 | n/a | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | - | n/a | 12 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.202 | n/a | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $19.25 | n/a | 31 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.57 | n/a | 3 | May 7, 2020 |
Exelixis
Oct 19, 2026
Reiterated: Buy
Price Target: $50 → $65
Current: $70.13
Upside: -7.31%
Foghorn Therapeutics
Oct 1, 2026
Downgraded: Hold
Price Target: n/a
Current: $2.13
Upside: -
Cellectis
Sep 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.04
Upside: -
Relay Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $21 → $26
Current: $17.28
Upside: +50.46%
Taysha Gene Therapies
Jun 23, 2026
Reiterated: Buy
Price Target: $8 → $11
Current: $4.00
Upside: +175.00%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.45
Upside: -
Intellia Therapeutics
Apr 28, 2026
Reiterated: Buy
Price Target: $28 → $30
Current: $11.66
Upside: +157.29%
CRISPR Therapeutics AG
Jan 30, 2026
Reiterated: Buy
Price Target: $86 → $80
Current: $49.99
Upside: +60.03%
Nuvation Bio
Nov 20, 2025
Reiterated: Buy
Price Target: $8 → $10
Current: $4.59
Upside: +117.86%
Benitec Biopharma
Nov 4, 2025
Reiterated: Buy
Price Target: $20 → $22
Current: $8.49
Upside: +159.13%
Oct 13, 2025
Reiterated: Buy
Price Target: $45
Current: $31.64
Upside: n/a
Sep 22, 2025
Reiterated: Buy
Price Target: $12 → $6
Current: $0.508
Upside: n/a
Sep 17, 2025
Reiterated: Buy
Price Target: $13
Current: $1.61
Upside: n/a
Sep 12, 2025
Reiterated: Buy
Price Target: $15
Current: $6.00
Upside: n/a
Aug 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.33
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: $6
Current: $4.44
Upside: n/a
Jun 10, 2025
Reiterated: Hold
Price Target: n/a
Current: -
Upside: n/a
Jun 3, 2025
Reiterated: Buy
Price Target: $4
Current: $0.202
Upside: n/a
May 9, 2025
Downgraded: Hold
Price Target: n/a
Current: $19.25
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
May 7, 2020
Rated: Hold
Price Target: n/a
Current: $2.57
Upside: n/a